? We have developed technology known as TIGER (Triangulation Identification for Genetic Evaluation of Risk), which provides a novel and universal approach to the identification of human and animal pathogens. The process uses mass spectrometry, signal processing, and base composition analysis of PCR amplification products from biologically conserved regions of microbial genomes to simultaneously identify the bacterial or viral agents without need for culture. While TIGER technology has been extensively validated and prototype instruments are being deployed to government biodefense laboratories, significant product development tasks must be achieved in order to commercialize the technology for human clinical diagnostics. We propose a cost-sharing model for development and validation of reagent products for identification of a broad range of respiratory and blood-borne infectious agents, including all bacteria and viruses on the NIAID ABC list. Our in-kind contribution will be development of hardware and analysis and control software to create an instrument suitable for clinical laboratory use. The clinical diagnostic system developed here will be a significant advance in human clinical diagnostics that will simultaneously provide national biodefense surveillance on an unprecedented scale. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
NIH Challenge Grants and Partnerships Program - Phase II-Coop.Agreement (UC1)
Project #
1UC1AI067232-01
Application #
7009763
Study Section
Special Emphasis Panel (ZAI1-MH-M (M3))
Program Officer
Beanan, Maureen J
Project Start
2005-08-01
Project End
2007-07-31
Budget Start
2005-08-01
Budget End
2007-07-31
Support Year
1
Fiscal Year
2005
Total Cost
$4,649,863
Indirect Cost
Name
Isis Pharmaceuticals, Inc.
Department
Type
DUNS #
361949092
City
Carlsbad
State
CA
Country
United States
Zip Code
92010